Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 175

1.

Survival Outcomes Associated With Female Primary Urethral Carcinoma: Review of a Single Institutional Experience.

Peyton CC, Azizi M, Chipollini J, Ercole C, Fishman M, Gilbert SM, Juwono T, Lockhart J, Poch M, Pow-Sang JM, Spiess PE, Wiegand L, Sexton WJ.

Clin Genitourin Cancer. 2018 May 18. pii: S1558-7673(18)30158-7. doi: 10.1016/j.clgc.2018.05.012. [Epub ahead of print]

PMID:
29859736
2.

Re: Stenting Prior to Cystectomy is an Independent Risk Factor for Upper Urinary Tract Recurrence: B. Kiss, M. A. Furrer, P. Y. Wuethrich, F. C. Burkhard, G. N. Thalmann and B. Roth J Urol 2017;198:1263-1268.

Zargar-Shoshtari K, Sexton WJ.

J Urol. 2018 Aug;200(2):457-458. doi: 10.1016/j.juro.2018.02.3095. Epub 2018 May 14. No abstract available.

PMID:
29772193
3.

Improved Outcomes of Enhanced Recovery After Surgery (ERAS) Protocol for Radical Cystectomy with Addition of a Multidisciplinary Care Process in a US Comprehensive Cancer Care Center.

Patel SY, Garcia Getting RE, Alford B, Hussein K, Schaible BJ, Boulware D, Lee JK, Gilbert SM, Powsang JM, Sexton WJ, Spiess PE, Poch MA.

World J Surg. 2018 May 10. doi: 10.1007/s00268-018-4665-z. [Epub ahead of print]

PMID:
29750321
4.

Multi-institutional Survival Analysis of Incidental Pathologic T3a Upstaging in Clinical T1 Renal Cell Carcinoma Following Partial Nephrectomy.

Russell CM, Lebastchi AH, Chipollini J, Niemann A, Mehra R, Morgan TM, Miller DC, Palapattu GS, Hafez KS, Sexton WJ, Spiess PE, Weizer AZ.

Urology. 2018 Jul;117:95-100. doi: 10.1016/j.urology.2018.04.002. Epub 2018 Apr 17.

PMID:
29678662
5.

Skeletal muscle microvascular and interstitial PO2 from rest to contractions.

Hirai DM, Craig JC, Colburn TD, Eshima H, Kano Y, Sexton WL, Musch TI, Poole DC.

J Physiol. 2018 Mar 1;596(5):869-883. doi: 10.1113/JP275170. Epub 2018 Jan 30.

PMID:
29288568
6.

The human, F-actin-based cytoskeleton as a mutagen sensor.

Clark NM, Garcia Galindo CA, Patel VK, Parry ML, Stoll RJ, Yavorski JM, Pinkason EP, Johnson EM, Walker CM, Johnson J, Sexton WJ, Coppola D, Blanck G.

Cancer Cell Int. 2017 Dec 12;17:121. doi: 10.1186/s12935-017-0488-5. eCollection 2017.

7.

Pathologic Predictors of Survival During Lymph Node Dissection for Metastatic Renal-Cell Carcinoma: Results From a Multicenter Collaboration.

Chipollini J, Abel EJ, Peyton CC, Boulware DC, Karam JA, Margulis V, Master VA, Zargar-Shoshtari K, Matin SF, Sexton WJ, Raman JD, Wood CG, Spiess PE.

Clin Genitourin Cancer. 2018 Apr;16(2):e443-e450. doi: 10.1016/j.clgc.2017.10.004. Epub 2017 Oct 17.

PMID:
29113770
8.

Development of a 90-Minute Integrated Noninvasive Urinary Assay for Bladder Cancer Detection.

Wallace E, Higuchi R, Satya M, McCann L, Sin MLY, Bridge JA, Wei H, Zhang J, Wong E, Hiar A, Mach KE, Scherr D, Egerdie RB, Ohta S, Sexton WJ, Meng MV, Weizer AZ, Woods M, Jansz GK, Zadra J, Lotan Y, Goldfarb B, Liao JC.

J Urol. 2017 Oct 20. pii: S0022-5347(17)77760-9. doi: 10.1016/j.juro.2017.09.141. [Epub ahead of print]

PMID:
29061538
9.

Evaluating the accuracy of intraoperative frozen section during inguinal lymph node dissection in penile cancer.

Chipollini J, Tang DH, Manimala N, Gilbert SM, Pow-Sang JM, Sexton WJ, Poch MA, Spiess PE.

Urol Oncol. 2018 Jan;36(1):14.e1-14.e5. doi: 10.1016/j.urolonc.2017.08.018. Epub 2017 Oct 9.

PMID:
29032883
10.

Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology.

Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Clark PE, Downs TM, Efstathiou JA, Flaig TW, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Preston MA, Sexton WJ, Siefker-Radtke AO, Sonpavde G, Tward J, Wile G, Dwyer MA, Gurski LA.

J Natl Compr Canc Netw. 2017 Oct;15(10):1240-1267. doi: 10.6004/jnccn.2017.0156.

PMID:
28982750
11.

Delay to Inguinal Lymph Node Dissection Greater than 3 Months Predicts Poorer Recurrence-Free Survival for Patients with Penile Cancer.

Chipollini J, Tang DH, Gilbert SM, Poch MA, Pow-Sang JM, Sexton WJ, Spiess PE.

J Urol. 2017 Dec;198(6):1346-1352. doi: 10.1016/j.juro.2017.06.076. Epub 2017 Jun 23.

PMID:
28652123
12.

Management of Renal Masses in an Octogenarian Cohort: Is There a Right Approach?

Tang DH, Nawlo J, Chipollini J, Gilbert SM, Poch M, Pow-Sang JM, Sexton WJ, Spiess PE.

Clin Genitourin Cancer. 2017 Dec;15(6):696-703. doi: 10.1016/j.clgc.2017.05.011. Epub 2017 May 10.

PMID:
28566202
13.

Sulforaphane for the chemoprevention of bladder cancer: molecular mechanism targeted approach.

Leone A, Diorio G, Sexton W, Schell M, Alexandrow M, Fahey JW, Kumar NB.

Oncotarget. 2017 May 23;8(21):35412-35424. doi: 10.18632/oncotarget.16015. Review.

14.

Neoadjuvant Chemotherapy in Elderly Patients With Bladder Cancer: Oncologic Outcomes From a Single Institution Experience.

Leone AR, Zargar-Shoshtari K, Diorio GJ, Sharma P, Boulware D, Gilbert SM, Powsang JM, Zhang J, Sexton WJ, Spiess PE, Poch MA.

Clin Genitourin Cancer. 2017 Aug;15(4):e583-e589. doi: 10.1016/j.clgc.2017.01.014. Epub 2017 Feb 1.

PMID:
28410909
15.

Does Implementing an Enhanced Recovery After Surgery Protocol Increase Hospital Charges? Comparisons From a Radical Cystectomy Program at a Specialty Cancer Center.

Chipollini J, Tang DH, Hussein K, Patel SY, Garcia-Getting RE, Pow-Sang JM, Gilbert SM, Sexton WJ, Spiess PE, Poch MA.

Urology. 2017 Jul;105:108-112. doi: 10.1016/j.urology.2017.03.023. Epub 2017 Mar 23.

PMID:
28342928
16.

Cytoreductive Nephrectomy for Renal Cell Carcinoma with Venous Tumor Thrombus.

Abel EJ, Spiess PE, Margulis V, Master VA, Mann M, Zargar-Shoshtari K, Borregales LD, Sexton WJ, Patil D, Matin SF, Wood CG, Karam JA.

J Urol. 2017 Aug;198(2):281-288. doi: 10.1016/j.juro.2017.03.011. Epub 2017 Mar 6.

PMID:
28268170
17.

Perioperative Management of a Patient With an Intrathecal Drug Delivery Device Infusing Ziconotide: A Case Report.

Patel S, Hafez O, Sexton WJ, Edwards DA.

A A Case Rep. 2017 Feb 15;8(4):78-80. doi: 10.1213/XAA.0000000000000432.

PMID:
28195861
18.

Author Reply.

Chipollini JJ, Tang DH, Patel SY, Garcia-Getting RE, Gilbert SM, Pow-Sang JM, Sexton WJ, Spiess PE, Poch MA.

Urology. 2017 May;103:148. doi: 10.1016/j.urology.2016.12.017. Epub 2017 Jan 17. No abstract available.

PMID:
28108090
19.

Identification of immunoglobulin V(D)J recombinations in solid tumor specimen exome files: Evidence for high level B-cell infiltrates in breast cancer.

Tong WL, Tu YN, Samy MD, Sexton WJ, Blanck G.

Hum Vaccin Immunother. 2017 Mar 4;13(3):501-506. doi: 10.1080/21645515.2016.1246095. Epub 2017 Jan 13.

20.

Bilateral benign renal oncocytomas and the role of renal biopsy: single institution review.

Leone AR, Kidd LC, Diorio GJ, Zargar-Shoshtari K, Sharma P, Sexton WJ, Spiess PE.

BMC Urol. 2017 Jan 12;17(1):6. doi: 10.1186/s12894-016-0190-2.

21.

Perioperative Transfusion of Leukocyte-depleted Blood Products in Contemporary Radical Cystectomy Cohort Does Not Adversely Impact Short-term Survival.

Chipollini JJ, Tang DH, Patel SY, Garcia-Getting RE, Gilbert SM, Pow-Sang JM, Sexton WJ, Spiess PE, Poch MA.

Urology. 2017 May;103:142-148. doi: 10.1016/j.urology.2016.12.015. Epub 2016 Dec 21.

PMID:
28011275
22.

T cell receptor gene recombinations in human tumor specimen exome files: detection of T cell receptor-β VDJ recombinations associates with a favorable oncologic outcome for bladder cancer.

Samy MD, Tong WL, Yavorski JM, Sexton WJ, Blanck G.

Cancer Immunol Immunother. 2017 Mar;66(3):403-410. doi: 10.1007/s00262-016-1943-1. Epub 2016 Dec 19.

PMID:
27995306
23.

Management of Urethral Recurrences: Urothelial and Nonurothelial.

Zargar-Shoshtari K, Sexton WJ, Poch MA.

Urol Clin North Am. 2016 Nov;43(4):515-521. doi: 10.1016/j.ucl.2016.06.012. Review.

PMID:
27717437
24.

NCCN Guidelines Insights: Bladder Cancer, Version 2.2016.

Clark PE, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Efstathiou JA, Flaig TW, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Kader AK, Kibel AS, Kuzel TM, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Petrylak D, Plimack ER, Pohar KS, Porter MP, Sexton WJ, Siefker-Radtke AO, Sonpavde G, Tward J, Wile G, Dwyer MA, Smith C.

J Natl Compr Canc Netw. 2016 Oct;14(10):1213-1224.

25.

Mass in Solitary Intrathoracic Kidney Within Bochdalek Hernia.

Sharma P, Keenan RJ, Sexton WJ.

Urology. 2016 Nov;97:e15-e16. doi: 10.1016/j.urology.2016.08.017. Epub 2016 Aug 20.

PMID:
27554626
26.

Surgical control and margin status after robotic and open cystectomy in high-risk cases: Caution or equivalence?

Sharma P, Zargar-Shoshtari K, Poch MA, Pow-Sang JM, Sexton WJ, Spiess PE, Gilbert SM.

World J Urol. 2017 Apr;35(4):657-663. doi: 10.1007/s00345-016-1915-2. Epub 2016 Aug 5.

PMID:
27495912
27.

Undiagnosed prostatic malignancy at the time of radical cystoprostatectomy after prior prostatic radiation therapy.

Sharma P, Zargar-Shoshtari K, Spiess PE, Sexton WJ, Poch MA.

Urol Ann. 2016 Apr-Jun;8(2):151-6. doi: 10.4103/0974-7796.163797.

28.

Is surgeon intuition equivalent to models of operative complexity in determining the surgical approach for nephron sparing surgery?

Sharma P, McCormick BZ, Zargar-Shoshtari K, Sexton WJ.

Indian J Urol. 2016 Apr-Jun;32(2):124-31. doi: 10.4103/0970-1591.179191.

29.

Clinical role of additional adjuvant chemotherapy in patients with locally advanced urothelial carcinoma following neoadjuvant chemotherapy and cystectomy.

Zargar-Shoshtari K, Kongnyuy M, Sharma P, Fishman MN, Gilbert SM, Poch MA, Pow-Sang JM, Spiess PE, Zhang J, Sexton WJ.

World J Urol. 2016 Nov;34(11):1567-1573. Epub 2016 Apr 12.

PMID:
27072536
30.

Change in Management Based on Pathologic Second Opinion Among Bladder Cancer Patients Presenting to a Comprehensive Cancer Center: Implications for Clinical Practice.

Luchey AM, Manimala NJ, Dickinson S, Dhillon J, Agarwal G, Lockhart JL, Spiess PE, Sexton WJ, Pow-Sang JM, Gilbert SM, Poch MA.

Urology. 2016 Jul;93:130-4. doi: 10.1016/j.urology.2016.01.048. Epub 2016 Mar 31.

PMID:
27041469
31.

Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial.

Haas NB, Manola J, Uzzo RG, Flaherty KT, Wood CG, Kane C, Jewett M, Dutcher JP, Atkins MB, Pins M, Wilding G, Cella D, Wagner L, Matin S, Kuzel TM, Sexton WJ, Wong YN, Choueiri TK, Pili R, Puzanov I, Kohli M, Stadler W, Carducci M, Coomes R, DiPaola RS.

Lancet. 2016 May 14;387(10032):2008-16. doi: 10.1016/S0140-6736(16)00559-6. Epub 2016 Mar 9. Erratum in: Lancet. 2016 May 14;387(10032):1998.

32.

Detection of Productively Rearranged TcR-α V-J Sequences in TCGA Exome Files: Implications for Tumor Immunoscoring and Recovery of Antitumor T-cells.

Gill TR, Samy MD, Butler SN, Mauro JA, Sexton WJ, Blanck G.

Cancer Inform. 2016 Feb 25;15:23-8. doi: 10.4137/CIN.S35784. eCollection 2016.

33.

Is percent seminoma associated with intraoperative morbidity during post-chemotherapy RPLND?

Russell CM, Sharma P, Agarwal G, Fisher JS, Richard GJ, Spiess PE, Pow-Sang JM, Poch MA, Sexton WJ.

Can J Urol. 2016 Feb;23(1):8127-34.

PMID:
26892052
34.

Effect of utilization of veno-venous bypass vs. cardiopulmonary bypass on complications for high level inferior vena cava tumor thrombectomy and concomitant radical nephrectomy.

Simon RM, Kim T, Espiritu P, Kurian T, Sexton WJ, Pow-Sang JM, Sverrisson E, Spiess PE.

Int Braz J Urol. 2015 Sep-Oct;41(5):911-9. doi: 10.1590/S1677-5538.IBJU.2014.0371.

35.

Valrubicin in refractory non-muscle invasive bladder cancer.

Sharma P, Zargar-Shoshtari K, Sexton WJ.

Expert Rev Anticancer Ther. 2015;15(12):1379-87. doi: 10.1586/14737140.2015.1115350. Epub 2015 Nov 16. Review.

PMID:
26569509
36.

Patients with ClearCode34-identified molecular subtypes of clear cell renal cell carcinoma represent unique populations with distinct comorbidities.

Haake SM, Brooks SA, Welsh E, Fulp WJ, Chen DT, Dhillon J, Haura E, Sexton W, Spiess PE, Pow-Sang J, Rathmell WK, Fishman M.

Urol Oncol. 2016 Mar;34(3):122.e1-7. doi: 10.1016/j.urolonc.2015.09.015. Epub 2015 Nov 3.

37.

Predictors of Postoperative Complications in Patients Who Undergo Radical Nephrectomy and IVC Thrombectomy: A Large Contemporary Tertiary Center Analysis.

Lue K, Russell CM, Fisher J, Kurian T, Agarwal G, Luchey A, Poch M, Pow-Sang JM, Sexton WJ, Spiess PE.

Clin Genitourin Cancer. 2016 Feb;14(1):89-95. doi: 10.1016/j.clgc.2015.09.007. Epub 2015 Sep 25.

PMID:
26453395
38.

Clinical Outcomes After Neoadjuvant Chemotherapy and Radical Cystectomy in the Presence of Urothelial Carcinoma of the Bladder With Squamous or Glandular Differentiation.

Zargar-Shoshtari K, Sverrisson EF, Sharma P, Gupta S, Poch MA, Pow-Sang JM, Spiess PE, Sexton WJ.

Clin Genitourin Cancer. 2016 Feb;14(1):82-8. doi: 10.1016/j.clgc.2015.08.006. Epub 2015 Aug 29.

PMID:
26411593
39.

Nephrectomy and inferior vena cava thrombectomy for renal cell carcinoma among patients with impaired renal function: defining predictors of outcomes.

Zargar-Shoshtari K, Ashouri K, Sharma P, Baumgarten A, Sexton WJ, Pow-Sang J, Spiess PE.

ANZ J Surg. 2016 Jan-Feb;86(1-2):44-8. doi: 10.1111/ans.13272. Epub 2015 Sep 15.

PMID:
26370725
40.

Robotic-Assisted Renal Surgery.

Emtage JB, Agarwal G, Sexton WJ.

Cancer Control. 2015 Jul;22(3):291-300. Review.

PMID:
26351884
41.

Evaluation of PAX8 Expression and Its Potential Diagnostic and Prognostic Value in Renal and Extra-Renal Ewing Sarcomas/PNETs.

Markow M, Bui MM, Lin HY, Lloyd M, Sexton WJ, Dhillon J.

Pathol Oncol Res. 2016 Jan;22(1):115-20. doi: 10.1007/s12253-015-9986-8. Epub 2015 Sep 9.

PMID:
26350056
42.

Minimally invasive post-chemotherapy retroperitoneal lymph node dissection for nonseminoma.

Sharma P, Sverrisson EF, Zargar-Shoshtari K, Fishman MN, Sexton WJ, Dickinson SI, Spiess PE, Poch MA, Gilbert SM, Pow-Sang JM.

Can J Urol. 2015 Aug;22(4):7882-9.

PMID:
26267026
43.

Preoperative Patient Reported Mental Health is Associated with High Grade Complications after Radical Cystectomy.

Sharma P, Henriksen CH, Zargar-Shoshtari K, Xin R, Poch MA, Pow-Sang JM, Sexton WJ, Spiess PE, Gilbert SM.

J Urol. 2016 Jan;195(1):47-52. doi: 10.1016/j.juro.2015.07.095. Epub 2015 Jul 31.

44.

Intratubular Germ Cell Neoplasia of the Testis, Bilateral Testicular Cancer, and Aberrant Histologies.

Sharma P, Dhillon J, Sexton WJ.

Urol Clin North Am. 2015 Aug;42(3):277-85. doi: 10.1016/j.ucl.2015.04.002. Epub 2015 Jun 6. Review.

PMID:
26216815
45.

Surveillance Following Nephron-Sparing Surgery: An Assessment of Recurrence Patterns and Surveillance Costs.

Zargar-Shoshtari K, Kim T, Simon R, Lin HY, Yue B, Sharma P, Spiess PE, Poch MA, Pow Sang J, Sexton WJ.

Urology. 2015 Aug;86(2):321-6. doi: 10.1016/j.urology.2015.05.013. Epub 2015 Jul 15.

PMID:
26187013
46.

Disparities in Interpretation of Primary Testicular Germ Cell Tumor Pathology.

Sharma P, Dhillon J, Agarwal G, Zargar-Shoshtari K, Sexton WJ.

Am J Clin Pathol. 2015 Aug;144(2):289-94. doi: 10.1309/AJCPJTX8R6CVWSRW.

PMID:
26185314
47.

Oncological control associated with surgical resection of isolated retroperitoneal lymph node recurrence of renal cell carcinoma.

Russell CM, Lue K, Fisher J, Kassouf W, Schwaab T, Sexton WJ, Tanguay S, Psutka SP, Thompson RH, Leibovich BC, Hanzly MI, Spiess PE, Boorjian SA.

BJU Int. 2016 Jun;117(6B):E60-6. doi: 10.1111/bju.13212. Epub 2015 Jul 18.

48.

Sarcopenia as a predictor of overall survival after cytoreductive nephrectomy for metastatic renal cell carcinoma.

Sharma P, Zargar-Shoshtari K, Caracciolo JT, Fishman M, Poch MA, Pow-Sang J, Sexton WJ, Spiess PE.

Urol Oncol. 2015 Aug;33(8):339.e17-23. doi: 10.1016/j.urolonc.2015.01.011. Epub 2015 Jun 18.

PMID:
26094169
49.

Implications of Definitive Prostate Cancer Therapy on Soft Tissue Margins and Survival in Patients Undergoing Radical Cystectomy for Bladder Urothelial Cancer.

Luchey AM, Lin HY, Yue B, Agarwal G, Gilbert SM, Lockhart J, Poch MA, Pow-Sang JM, Spiess PE, Sexton WJ.

J Urol. 2015 Nov;194(5):1220-5. doi: 10.1016/j.juro.2015.05.091. Epub 2015 Jun 6.

PMID:
26055823
50.

Oncological and functional outcomes of salvage renal surgery following failed primary intervention for renal cell carcinoma.

Abarzua-Cabezas FG, Sverrisson E, De La Cruz R, Spiess PE, Haddock P, Sexton WJ.

Int Braz J Urol. 2015 Jan-Feb;41(1):147-54. doi: 10.1590/S1677-5538.IBJU.2015.01.20.

Supplemental Content

Loading ...
Support Center